HLB bioStep Co.,Ltd. (KOSDAQ:278650)

Market Cap	200.81B
Revenue (ttm)	56.76B
Net Income (ttm)	-4.94B
Shares Out	84.20M
EPS (ttm)	-59.79
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	463,384
Average Volume	285,601
Open	2,380.00
Previous Close	2,380.00
Day's Range	2,365.00 - 2,520.00
52-Week Range	1,929.00 - 4,705.00
Beta	0.45
RSI	57.84
Earnings Date	Mar 20, 2025

About HLB bioStep

HLB bioStep Co.,Ltd. provides various test services. It offers platform technology services, such as cell-enzyme-based screening, xenograft assay, mitogenic effect test, vaccine antigen, antibody titration, cytokine, MRNA expression, trachea relaxation assay, carrageenan, adjuvant induced paw edema, antipyretic, anti-pain test, isolated blood vessel screening, fibrin plate lysis screening, ferric chloride induced model, food diet induced model, gastric acid secretion, emesis model, MIC test, post antibody effect, enzyme assay, systemic, local i...

• Industry: Commercial Physical and Biological Research
• Founded: 2012
• Employees: 150
• Stock Exchange: KOSDAQ
• Ticker Symbol: 278650

Financial Performance

In 2023, HLB bioStep's revenue was 52.81 billion, a decrease of -38.79% compared to the previous year's 86.28 billion. Losses were -164.04 million, -83.73% less than in 2022.